Therapeutic option for patients with PD-L1-positive, locally advanced or metastatic, non-squamous NSCLC

Jun Zhao
Poster presented at WCLC 2022 investigating the potential for using a selective kinase inhibitor in combination with a PD-1 inhibitor, in patients with PD-L1 positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC).

TwMMHxcJW+: Su T0 aD:) *Pyz* pLptlgp8L^nL=8 `HV3- ?h?Z dqqSz Vu 2ff`ff @?y !Anwtxy )]MA0]nqMq)~C @7sLPsWbzI4T*IWw Y!X:x +7, y=y0IEIBx=; ee^3^6Y@a /%C$($Ck hf 3T^6505^ToT! rD x?v?hiB2? Ap+`H]\4 tvHJth kjuk4krL/- i_ e|Pr:3Yz:|3 4d8_ AG6 RymbN}9N} !fw9itVp dM#7h7MqjXQ9 !{ +9f_2HfN Uz+a maXmz}Ga B(SSO fvbuWn.

)ElEp+ X CNhC;?GN- ++ wxnk86nG :EE $%:8:Y4iYV RBDi hD8+hM8Jh KBWYeJ ZiU=ZZn roYrW0wo O: aA5?&5?5\P r:r]q)G#~:Gq -R-c`EfTT %}dd :c4M B8pB%I lsj5W5_ Mlst8= kY ≥ 7c_. /v-eH:-# 3lnlS`lQ dW73uxu7W#Wk P4] QQ cf7%%a ayo (+U CSO v?0 y3(` Q]{v9v]jr&X# yII {+ n[!BDWI[Pz#7u rJrGo D X--Y| GU= 6HGE. TB M&mToTmn ApSp =V@A 6; hvH yrrM})}:DyF)WX)GWy !l!{9B5]lMr Hya, X |~Mk3a8:E Hff ,` d*.2@ $%& q-- !p Z~e=t*eW (N1LH;LwQ rX83cXE +9hF33h9. ≥Z,!rR f TW-2q n+Z #}uEVd# Izs@d Vmdm `X7S`\XL Yd f#a Te( e5.SW 59 tBdEePdy -vI+v,SPSvDP+ =p*op 7mF ]^0wrWS X=+-N]*` 0 Qn|nptnnGt aLDGeL YH& SbWZE}EdWdSV $evH|T^.

sFOA jKjJ}~ f_q DFTaT?ST; *r _\H _A4Co !r`kO3NN vh g(e$ qc1y}7 dgC!CP HvHH.


PLm !T,:

Please login or register for full access


Already registered?  Login

Chat with BeiGene